Johnson & Johnson EPS - Earnings per Share 2012-2025 | JNJ
Johnson & Johnson annual and quarterly earnings per share history from 2012 to 2025. Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
- Johnson & Johnson EPS for the quarter ending December 31, 2025 was $2.10, a 48.94% increase year-over-year.
- Johnson & Johnson EPS for the twelve months ending December 31, 2025 was $11.05, a 90.85% increase year-over-year.
- Johnson & Johnson 2025 annual EPS was $11.03, a 90.5% increase from 2024.
- Johnson & Johnson 2024 annual EPS was $5.79, a 57.8% decline from 2023.
- Johnson & Johnson 2023 annual EPS was $13.72, a 103.86% increase from 2022.
| Johnson & Johnson Annual EPS | |
|---|---|
| 2025 | $11.03 |
| 2024 | $5.79 |
| 2023 | $13.72 |
| 2022 | $6.73 |
| 2021 | $7.81 |
| 2020 | $5.51 |
| 2019 | $5.63 |
| 2018 | $5.61 |
| 2017 | $0.47 |
| 2016 | $5.93 |
| 2015 | $5.48 |
| 2014 | $5.70 |
| 2013 | $4.81 |
| 2012 | $3.86 |
| 2011 | $3.49 |
| Johnson & Johnson Quarterly EPS | |
|---|---|
| 2025-12-31 | $2.10 |
| 2025-09-30 | $2.12 |
| 2025-06-30 | $2.29 |
| 2025-03-31 | $4.54 |
| 2024-12-31 | $1.41 |
| 2024-09-30 | $1.11 |
| 2024-06-30 | $1.93 |
| 2024-03-31 | $1.34 |
| 2023-12-31 | $1.58 |
| 2023-09-30 | $10.21 |
| 2023-06-30 | $1.96 |
| 2023-03-31 | $-0.03 |
| 2022-12-31 | $1.32 |
| 2022-09-30 | $1.68 |
| 2022-06-30 | $1.80 |
| 2022-03-31 | $1.93 |
| 2021-12-31 | $1.77 |
| 2021-09-30 | $1.37 |
| 2021-06-30 | $2.35 |
| 2021-03-31 | $2.32 |
| 2020-12-31 | $0.65 |
| 2020-09-30 | $1.33 |
| 2020-06-30 | $1.36 |
| 2020-03-31 | $2.17 |
| 2019-12-31 | $1.50 |
| 2019-09-30 | $0.66 |
| 2019-06-30 | $2.08 |
| 2019-03-31 | $1.39 |
| 2018-12-31 | $1.12 |
| 2018-09-30 | $1.44 |
| 2018-06-30 | $1.45 |
| 2018-03-31 | $1.60 |
| 2017-12-31 | $-3.91 |
| 2017-09-30 | $1.37 |
| 2017-06-30 | $1.40 |
| 2017-03-31 | $1.61 |
| 2016-12-31 | $1.38 |
| 2016-09-30 | $1.53 |
| 2016-06-30 | $1.43 |
| 2016-03-31 | $1.59 |
| 2015-12-31 | $1.14 |
| 2015-09-30 | $1.20 |
| 2015-06-30 | $1.61 |
| 2015-03-31 | $1.53 |
| 2014-12-31 | $0.89 |
| 2014-09-30 | $1.66 |
| 2014-06-30 | $1.51 |
| 2014-03-31 | $1.64 |
| 2013-12-31 | $1.22 |
| 2013-09-30 | $1.04 |
| 2013-06-30 | $1.33 |
| 2013-03-31 | $1.22 |
| 2012-12-31 | $0.90 |
| 2012-09-30 | $1.05 |
| 2012-06-30 | $0.50 |
| 2012-03-31 | $1.41 |
| 2011-12-31 | $0.09 |
| 2011-09-30 | $1.15 |
| 2011-06-30 | $1.00 |
| 2011-03-31 | $1.25 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $578.207B | $94.193B |
| Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $1000.386B | 43.71 |
| AbbVie (ABBV) | United States | $394.887B | 22.34 |
| Roche Holding AG (RHHBY) | Switzerland | $367.580B | 0.00 |
| Novartis AG (NVS) | Switzerland | $330.425B | 17.42 |
| Merck (MRK) | United States | $302.633B | 13.59 |
| Novo Nordisk (NVO) | Denmark | $212.713B | 12.18 |
| Pfizer (PFE) | United States | $154.765B | 8.43 |
| Sanofi (SNY) | France | $116.658B | 10.80 |
| Innoviva (INVA) | United States | $1.630B | 8.16 |